Global cord blood corporation obtained injunction order against blue ocean in respect of purported egm

Hong kong , july 6, 2022 /prnewswire/ -- global cord blood corporation (nyse: co, "gcbc" or the "company"), china's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that an injunction order (the "order") previously obtained by the company on june 15, 2022 from the grand court of the cayman islands (the "court") against blue ocean structure investment company limited ("blue ocean") was officially issued by the court on july 6, 2022. the order provides, among other things, that: until further order of the court, any resolution or resolutions ("resolutions") that might be passed or purported to be passed at any extraordinary general meeting of the company to be held or purporting to be held on june 16, 2022 ("the purported egm") or other meeting held or purporting to be held pursuant to a notice of extraordinary general meeting dated june 3, 2022 (on june 16, 2022 or any other date) shall not take effect and shall not be implemented, and blue ocean must not: rely or purport to rely upon any such resolutions; and/or seek to convene or convene any extraordinary general meeting of the company or other meeting.
CO Ratings Summary
CO Quant Ranking